Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + Ruxolitinib in Treatment-naïve Myelofibrosis
NCT04562389Phase 3Active, not recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Mar 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of selinexor in myelofibrosis (MF) (5 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoints: Spleen Volume Reduction >= 35% at 24 weeks, Absolute mean change in Total Symptom Score at 24 weeks and 3 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04562389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562389.